The 112 volunteers included 24 women and 3 transgender individuals; 68% were from the university clinic, and 32% were from the urban clinic. Mean age was 44.2 years. The mean 25(OH)D level was 22.5 ng/mL; mean 1,25(OH) 2 D level was 23.5 pg/mL. Twenty-two percent had 25(OH)D Յ10 ng/mL; 53% had values Ͻ20 ng/mL, and 73% were Յ30 ng/mL. There was no association between vitamin D and CD4. A nonlinear relationship between viral load and 1,25(OH) 2 D was found. For 1,25(OH) 2 D below 32 pg/mL, for each 10 pg/mL decrease in 1,25(OH) 2 D, (log10) viral load increased by 0.84 (95% CI: 0.16 -1.51, P ϭ .015). For 1,25(OH) 2 D above 32 pg/mL, for each 10 pg/mL increase in 1,25(OH) 2 D, (log10) viral load increased by 0.36 (95% CI: 0.15-0.57, P ϭ .0009). 
ylase (8) . Emerging research highlights its potential role in aiding the human immune system with serious infections, including HIV (2, 9 -11) . Activated monocytes and macrophages produce the 1,25(OH) 2 D-dependent antimicrobial peptide, cathelicidin (9) . Recent work defines the central role of cathelicidin in the immune response to tuberculosis, and possibly other viral infections, including HIV, and in vitro studies demonstrate cathelicidin's ability to inhibit HIV replication in CD4ϩ T cells and macrophages (9, 10, (12) (13) (14) .
Vitamin D deficiency refers to a low serum 25-hydroxyvitamin D (25[OH]D) concentration, whereas levels of 1,25(OH) 2 D are usually maintained at normal or elevated levels in the face of low 25(OH)D status (15) (16) (17) . The cut points chosen to define deficiency or inadequacy are controversial (15, 16) . Factors that likely contribute to low vitamin D in the body include season and latitude, skin color, and sun exposure and are complicated by polymorphisms in the vitamin D receptor and variations in vitamin D binding protein (1, 8, 18) . Vitamin D deficiency is widespread among those living with HIV/AIDS (19 -24) and recent reports associate low 25(OH)D levels with more rapid progression of disease, higher all-cause mortality, and increased mother-to-child transmission of HIV (24, 25) . Decreased serum concentrations of 1,25(OH) 2 D are usually only seen with chronic renal disease or in rare conditions involving mutations in the converting enzyme (17) . However, past studies find low levels of 1,25(OH) 2 D among HIV cohorts, including an associated increase in mortality, and a positive correlation between levels of 1,25(OH) 2 D and CD4ϩ T cells, the primary targets for HIV infection (21) (22) (23) . Decreased levels of 1,25(OH) 2 D in the setting of HIV infection may be related to increased levels of TNF-␣ or other inflammatory mediators, decreasing the conversion of 25(OH)D to 1,25(OH) 2 D via 1-␣-hydroxylase, effects of antiretroviral therapy (ART), and possibly increased utilization (2, 26, 27) .
There is little known about the relationship between 25(OH)D and 1,25(OH) 2 D levels and HIV viral load. We hypothesized that low levels of 1,25(OH) 2 D and/or 25(OH)D would be associated with a lack of virologic suppression, as evidenced by elevated HIV viral loads. To evaluate this hypothesis, we undertook a cross-sectional study among HIV/AIDS patients receiving care at 2 sites, a university-based HIV clinic in Madison, Wisconsin, and a community-based, inner city HIV clinic in Milwaukee, Wisconsin.
Materials and Methods
We conducted a cross-sectional, observational study among adults living with HIV. The study was reviewed and approved by 
Settings
Volunteers were recruited from 2 sites. The university-based clinic cares for approximately 600 nonincarcerated adults living with HIV/AIDS, 20% of which are women and 20% of which receive care through the federally funded Title III Ryan White Grant. The second site was a community-based HIV clinic, housed in a federal funding-qualified community health center in Milwaukee, Wisconsin and serves an urban population of adults living with HIV/AIDS, most of which receive care through federally and or state-funded programs. The clinic serves approximately 180 patients: 90% are African-American and 25% of the patients are women.
All nonpregnant, nonincarcerated adults over the age of 18, able to give informed consent, living with HIV/AIDS, and receiving care at one of these clinics were eligible for the study. Recruitment took place at the university clinic between January 2010 and April 2011 and at the community clinic between January 2011 and April 2011, and data collection continued through October 2011. The sample size of 112 subjects was chosen to provide 80% power to detect a correlation of 0.268 between 1,25(OH) 2 D level and HIV viral load using a 2-sided 5% level test.
Study procedures included a single blood draw, which was usually done in conjunction with routine HIV monitoring laboratory tests, and a self-administered questionnaire regarding vitamin D dietary intake and UV light exposure. All 25(OH)D levels were determined using HPLC (University of Wisconsin Hospital and Clinics Clinical Laboratory, Madison, Wisconsin) and all 1,25(OH) 2 D levels were analyzed by quantitative RIA (ARUP Laboratories, Salt Lake City, Utah).
Statistical analysis
Participant characteristics were compared between clinics using 2 sample t tests for continuous variables and 2 tests for categorical variables (Table 1) . For the purpose of this study, 25(OH)D levels were defined as sufficient (Ն30 ng/mL, 75 nmol/ L), insufficient (21-29 ng/mL, 52.5-72.5 nmol/L), inadequate (Յ20 ng/mL, 50 nmol/L), and deficient (Յ10 ng/mL, 25 nmol/L).
HIV viral load, CD4ϩ T cell absolute number, and CD4% were modeled as smooth, nonlinear functions of vitamin D levels using generalized additive models (28) . The following variables were evaluated as potential confounders of these relationships: age, season, race, clinic, sex, insurance, Hispanic ethnicity, du-ration of HIV, diabetes, hepatitis C, renal disease, mental health, substance abuse, osteoporosis, antiretrovirus, and current use of vitamin D supplements. Stepwise variable selection based on Aikaike Information Criterion (AIC) was used to identify potential confounders associated with vitamin D levels first (29) . From this reduced list of potential confounders, a final list of confounders for each outcome (viral load, absolute CD4ϩ T-cell count, and CD4%) was then identified using stepwise selection based on AIC. These variables were then included as adjustment variables in the final models for viral load, CD4ϩ T cell, and CD4%. Change point models were used to characterize significant nonlinear relationships of vitamin D levels with these outcomes (30) .
A nominal P value of .05 was regarded as statistically significant. Analyses were performed in R version 2.13.1 (31) (R Foundation for Statistical Computing, Vienna, Austria). Generalized additive models were fit using the mgcv package (32) .
Results

Volunteers
Seventy-six volunteers were recruited from the university clinic (68%) and 36 volunteers were recruited from the Table 2 . The volunteers were 76% men, and 81% were taking ART at the time of the study. Compared with the university clinic, the urban community clinic volunteers had more comorbid disease (diabetes and hepatitis C), a greater percentage of volunteers with mental health disease and substance abuse, and a higher percentage of participants receiving federal or state subsidized insurance coverage based on need (not including Medicare recipients). African-American volunteers made up approximately 39% of the total study population; however, the majority came from the urban community clinic, whose participants were 97% African-American.
Vitamin D levels
The average 25(OH)D level was 22.5 ng/mL (SD 14.3 ng/mL) among all participants. The mean 1,25(OH) 2 D level was 23.5 pg/mL (SD 21.8 pg/mL) ( Table 2) Figure 2 .
Similar results were seen in both clinics. At the university-based clinic, for each 10 pg/mL decrease in 1,25(OH) 2 D below 32 pg/mL, the (log10) viral load increased by 0.79 (95% CI: 0.33-2.12 P ϭ .016). For each 10 pg/mL increase in 1,25(OH) 2 D above 32 pg/mL, the (log10) viral load increased by 0.35 (95% CI: 0.09 -0.60, P ϭ .009). At the inner city clinic, for each 10 pg/mL decrease in 1,25(OH) 2 D below 32 pg/mL, the (log10) viral 
Vitamin D levels and antiretroviral therapy
Multivariate analysis revealed that the following antiretroviral agents predicted vitamin D levels (25 
Discussion
Our study found vitamin D (25[OH]D) inadequacy (Յ20 ng/mL) in 53% and deficiency (Յ10 ng/mL) in 22% of this mixed population of HIV/AIDS ambulatory patients. Applying the often recommended cut point of 30 ng/mL, 73.2% of volunteers in our study had vitamin D insufficiency. Our results are consistent with the recent reports in the literature of HIV cohorts, which find vitamin deficiency rates between 60% and 90% (19, 20, 24) .
The high degree of inadequate vitamin D levels among African-Americans in our study is consistent with the general population as 97% of non-Hispanic blacks are estimated to have vitamin D insufficiency or deficiency (33) . The final model for relating 1,25(OH) 2 D levels and viral load did not include race, as this was not found to predict viral load on its own. However, the enrollment site (clinic) was found to predict viral load and was in the final model. Milwaukee's community clinic volunteers were overwhelmingly African-American (97%). Therefore, race was likely accounted for with the inclusion of this variable. To be certain, we ran the model separately for each clinic and for African-American versus non-African-American volunteers and the results did not change dramatically. However, the relationship between 1,25(OH) 2 D and HIV viral load appeared to be stronger for non-African-Americans (for each 10 pg/mL below 32 pg/mL, log 10 viral load increased by 0.65 in African-Americans vs 1.96 in nonAfrican-Americans). One explanation for this difference is a possible decreased responsiveness to 1,25(OH) 2 D in African-Americans, leading to a less potent antiviral or supportive immunomodulatory role for vitamin D in this population. Further large studies are needed to clarify this potential difference.
Various antiretrovirals are now well known to interact with vitamin D metabolism (26, 27) . Our study found multiple antiretrovirals to be correlates of vitamin D levels. However, we hesitate to make any robust conclusions given the small sample size and the fact that the agents were analyzed independently of one another rather than accounting for coformulations and coadministration. Current ART (any) predicted 25(OH)D but not 1,25(OH) 2 D, the active form of vitamin D.
Although recent publications have linked lower 25(OH)D to lower CD4ϩ T cell counts and higher viral loads (34), as well as increased morbidity and mortality, (14) . We found an inverse relationship of low 1,25(OH) 2 D levels associated with high viral loads. We anticipated 1,25(OH) 2 D levels to be low in the face of high viral loads as, perhaps, the hormone is depleted in response to virus triggering 1,25(OH) 2 D-dependent immune defense mechanisms. Alternatively, the low levels could be related to an inability to covert 25(OH)D to its active form in response to HIV due to extremely low 25(OH)D levels (Յ4 ng/mL) (35) . However, only 4 of the 112 volunteers had levels 25(OH)D levels Յ4 ng/mL, making this an unlikely explanation. Finally, renal conversion of 25(OH)D to 1,25(OH) 2 D may be inhibited by the increased levels of TNF-␣ associated with HIV viremia, indirectly linking viral load to 1,25(OH)2D levels (23, 36 -39) .
Surprisingly, increasing 1,25(OH) 2 D levels were associated with higher viral loads as well, creating a U-shaped association with a change point of 32 pg/mL (Figure 2 ). It is unclear exactly why 1,25(OH) 2 D levels should be high in the setting of high amounts of detectable virus. The U-shaped curve found in this study is likely reflective of a complex role for vitamin D in HIV infection, which is not yet well understood and deserves further study.
One possible explanation for the association of increasing 1,25(OH) 2 (2, 41, 42) . However, these results were not consistent among studies and recent work strengthens the argument for an antiviral role for vitamin D in HIV infection (2, 10, 14, 43) .
We found 25(OH)D levels and HIV viral load to be only weakly associated and not statistically significant (P ϭ .36), consistent with the understanding that 25(OH)D metabolism in HIV infection is complex. Factors beyond viral load, and those factors accounted for in our model, likely influence 25(OH)D levels as well. For example, we were unable to include measures for obesity in our analysis due to lack of available data, and obesity could be an important confounder. Additionally, individual antiretroviral agents were not included in the final multivariate model, namely efavirenz, which is associated with 25(OH)D deficiency in HIV populations (27, 36, 44) . Finally, having an undetectable HIV viral load was associated with a lower odds ratio of vitamin D deficiency in a recent large, cohort study (34) . Therefore, it is possible a larger sample size is needed to demonstrate a significant relationship between HIV viral load and 25(OH)D.
Our study had several limitations. First, the enrollment occurred across seasons and, although this was accounted for in the analysis, an ideal study would be done in a tighter timeframe to minimize the effect of season on vitamin D levels. Body mass index, found as a risk factor for low vitamin D status in HIV patients, was not accounted for in the analysis because weight and height measurements were not consistently recorded in the electronic medical records (20) .
The volunteers for this study were recruited from 2 distinct and different populations. Notably, the Milwaukee clinic had 25(OH)D and 1,25(OH) 2 D levels 17 ng/mL and 13 pg/mL lower than those from the university clinic (P Ͻ .0001 and Ͻ.0034, respectively) and 58% of the volunteers from that site had 25(OH)D levels Յ10 ng/mL. The reason for 2 sites was to enhance the diversity of the study population and meet recruitment goals. We attempted to identify any potential confounding due to clinic in the analysis by including it in the models and analyzing the clinic populations separately as well as analyzing based on African-American vs nonAfrican-American, given the community clinic was 97% African-American.
Finally, our study was small and cross-sectional and included only a single blood draw, thus limiting the ability to draw robust conclusions from the findings. The small sample size likely contributed to the wide confidence in-tervals found. A larger, prospective study evaluating 1,25(OH) 2 D levels and viral loads at multiple time points and studies evaluating the effect of vitamin D supplementation on viral load would help to understand better the complex and important role vitamin D likely plays in HIV infection.
